butyrate HDAC inhibition
Selected indexed studies
- Butyrate Lowers Cellular Cholesterol through HDAC Inhibition and Impaired SREBP-2 Signalling. (Int J Mol Sci, 2022) [PMID:36555149]
- Inhibition of HDAC activity directly reprograms murine embryonic stem cells to trophoblast stem cells. (Dev Cell, 2024) [PMID:38823394]
- Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer. (Cancer Cell, 2024) [PMID:39303724]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Butyrate Lowers Cellular Cholesterol through HDAC Inhibition and Impaired SREBP-2 Signalling. (2022) pubmed
- Inhibition of HDAC activity directly reprograms murine embryonic stem cells to trophoblast stem cells. (2024) pubmed
- Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer. (2024) pubmed
- Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. (2013) pubmed
- Microbiota-derived butyrate inhibits cDC development via HDAC inhibition, diminishing their ability to prime T cells. (2024) pubmed
- Ketone bodies as signaling metabolites. (2014) pubmed
- Microbiota metabolite butyrate constrains neutrophil functions and ameliorates mucosal inflammation in inflammatory bowel disease. (2021) pubmed
- Butyrate acts through HDAC inhibition to enhance aryl hydrocarbon receptor activation by gut microbiota-derived ligands. (2022) pubmed
- Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor. (2013) pubmed
- Butyrate reverses ferroptosis resistance in colorectal cancer by inducing c-Fos-dependent xCT suppression. (2023) pubmed